Microbix Biosystms (MBX) AI Stock Analysis

• Market Cap: C$32.56M
• Dividend Yield: N/A
• Average Volume (3M): 57.61K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.19
• Revenue Growth: -26.81%
• EPS Growth: -161.24%
• Country: CA
• Employees: 100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 138,553,380
• 10 Day Avg. Volume: 59,614
• 30 Day Avg. Volume: 57,610
• PEG Ratio: 0.10
• Price to Book (P/B): 1.33
• Price to Sales (P/S): 1.98
• P/FCF Ratio: -42.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 108.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.22 ▼(-6.67% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held down primarily by weakened financial performance (return to losses and negative cash flow) and only mildly supportive technicals (negative MACD and below longer-term averages). The earnings call adds some offset from improving sequential trends, cash collections, and operational initiatives, but near-term revenue/margin uncertainty—especially tied to China—keeps the overall score below average.

Positive Factors

Growing QAPs (external quality control) business

QAPs are recurring, mission‑critical controls used by labs and diagnostics firms. A 15% YoY increase and broader distribution reduce customer concentration and create steady, repeatable demand, improving revenue visibility and resilience versus one‑off antigen sales volatility.

Relatively healthy balance sheet and manageable leverage

Low leverage (~0.24 D/E) and a meaningful equity base provide financial flexibility to fund operations, product commercialization, and working capital needs. This moderates solvency risk and supports multi‑quarter execution while revenues recover, preserving strategic optionality.

Commercialization of recombinant antigens improving supply and margins

Bringing recombinant antigen production in‑house reduces reliance on external suppliers/distributors, addresses supply security (notably China exposure), and enables lower unit costs and higher gross margins over time. This vertical capability is a structural margin and competitiveness enhancer.

Negative Factors

Large YoY revenue decline, driven by China distributor inactivity

A ~30% YoY revenue drop highlights material customer/concentration risk and geographic dependency. Reliance on distributor channels that can go inactive creates persistent volatility and reduces predictability of cash generation and scale needed to cover fixed costs.

Negative operating and free cash flow (ongoing cash burn)

Sustained negative OCF and FCF imply the business is burning cash to fund operations. This strains the company’s runway, limits capacity to invest in commercialization or scale recombinant production, and increases reliance on external funding or working‑capital timing to bridge results.

Profitability depends on reaching revenue breakeven band

Profitability hinges on achieving and sustaining >$5.5M quarterly revenue so fixed overheads are absorbed. Until that scale is consistently reached, margins remain vulnerable to volume swings and timing of large orders, making earnings recovery uncertain and execution‑sensitive.

Microbix Biosystms Business Overview & Revenue Model

Company Description

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

How the Company Makes Money

Microbix Biosystems generates revenue primarily through the sale of its proprietary products, which include antigens and quality control materials used in diagnostic testing. Their revenue model is based on direct sales to diagnostic laboratories, pharmaceutical companies, and other healthcare providers. Key revenue streams include the sale of viral and bacterial antigens, which are vital for various tests, as well as quality control products that ensure the reliability of laboratory results. Additionally, the company benefits from partnerships with other biotech firms and research institutions, which can lead to collaborative projects and increased sales opportunities. Significant contracts and collaborations with major players in the diagnostics industry further enhance its revenue potential, allowing Microbix to expand its market presence and leverage its product offerings effectively.

Microbix Biosystms Financial Statement Overview

Summary

Financials are pressured: TTM revenue fell ~9.8%, the company swung back to a net loss (~-$4.3M) and both operating cash flow (~-$3.5M) and free cash flow (~-$4.2M) are negative. The balance sheet is a relative positive with moderate leverage (debt-to-equity ~0.24), but profitability and cash generation have weakened versus FY2024.

Income Statement

Results have deteriorated meaningfully in TTM (Trailing-Twelve-Months): revenue fell about 9.8% and the company is back to a sizeable net loss (about -$4.3M) after a profitable FY2024. While gross margin remains solid around ~53%, operating profitability is weak with negative EBIT and a negative net margin, pointing to cost pressure and/or lower volume. The key positive is that margins are still supported at the gross level, but the recent swing from strong FY2024 profitability to losses reduces earnings quality and visibility.

Balance Sheet

The balance sheet is relatively healthy: leverage looks manageable with debt-to-equity around ~0.24 and equity representing a meaningful portion of the capital base (TTM equity ~$26.6M vs. assets ~$36.6M). However, returns have turned negative in TTM (negative return on equity), reflecting that the balance sheet strength is not currently translating into shareholder profitability. Overall, financial risk from leverage appears moderate, but earnings weakness is the main balance-sheet-related concern.

Cash Flow

Cash generation is currently a weak spot: TTM (Trailing-Twelve-Months) operating cash flow is negative (about -$3.5M) and free cash flow is also negative (about -$4.2M), signaling cash burn. This contrasts with FY2024, when the company generated positive operating cash flow and positive free cash flow. The stated free cash flow growth is strong in TTM, but it is coming off a negative base and does not offset the fact that cash flow remains negative today.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	16.76M	18.59M	25.39M	16.51M	19.08M	18.59M
Gross Profit	7.83M	9.85M	15.39M	7.48M	11.12M	11.04M
EBITDA	-1.59M	428.23K	6.21M	1.96M	3.73M	5.66M
Net Income	-4.27M	-2.25M	3.52M	-39.48K	1.79M	1.63M
Balance Sheet
Total Assets	36.59M	37.41M	38.10M	35.65M	33.15M	28.83M
Cash, Cash Equivalents and Short-Term Investments	9.10M	12.11M	12.96M	11.61M	13.49M	9.99M
Total Debt	8.11M	6.77M	6.40M	6.65M	5.82M	7.74M
Total Liabilities	9.98M	9.62M	9.80M	11.03M	8.21M	10.27M
Stockholders Equity	26.61M	27.79M	28.30M	24.62M	24.94M	18.56M
Cash Flow
Free Cash Flow	-4.24M	-877.58K	2.44M	-2.11M	1.44M	804.20K
Operating Cash Flow	-3.48M	-80.29K	4.35M	-1.09M	3.47M	2.11M
Investing Cash Flow	-764.61K	-797.30K	-1.91M	-1.02M	-2.03M	-622.34K
Financing Cash Flow	289.54K	27.00K	-1.08M	229.21K	2.06M	8.41M

Microbix Biosystms Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MBX, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.23, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.49 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MBX.

Microbix Biosystms Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	45 Neutral	C$32.56M	-6.85	-8.01%	―	-26.81%	-161.24%
DTC	45 Neutral	C$35.00M	-6.55	―	―	―	72.92%
BCT	44 Neutral	C$39.88M	-0.63	-409.25%	―	―	62.01%

Microbix Biosystms Corporate Events

Microbix Q1 Revenue Rebounds Sequentially as China Antigen Sales Slide

Microbix Biosystems reported first-quarter fiscal 2026 revenue of $4.2 million, up 13% from the prior quarter but 30% below the same period last year, reflecting ongoing recovery after setbacks with two major clients in 2025. The quarter was marked by sharply lower antigen sales into China, partially offset by rising sales of branded QAPs products, resulting in a 41% gross margin and a controlled net loss of $1.17 million.

Management emphasized that the revenue and loss levels were in line with its 2026 budget and highlighted a strong balance sheet, including a current ratio of 7.51 and modest leverage with a 0.38 debt-to-equity ratio. The company is aggressively pursuing new client programs and expanding its product portfolio to restore sales above breakeven, improve margins, and create long-term shareholder value in both its diagnostics business and its Kinlytic urokinase drug program.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Q1 Revenue Rebounds Sequentially but China Slump Drives Loss

Microbix reported first-quarter fiscal 2026 revenue of C$4.2 million, up 13% from the prior quarter but down 30% year over year, as a steep drop in antigen sales to its Chinese distributor outweighed growth in other antigen customers and a 15% increase in QAPs revenues. The weaker sales mix and lower production volumes compressed gross margins to 41% from 62%, resulting in a net loss of C$1.17 million and negative operating cash flow, though the company maintained a strong liquidity position with a current ratio of 7.51 and a modest debt-to-equity ratio.

Management is focused on rebuilding revenues above breakeven by adding new client programs and customers across all business lines, leveraging recent investments in capabilities and capacity. The company aims to improve margins and restore profitability while pursuing growth in both its diagnostics-oriented operations and its fully funded Kinlytic urokinase thrombolytic drug program, positioning itself to create longer-term shareholder value despite recent client setbacks.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Wins College of American Pathologists as New QAP Client

Microbix Biosystems has secured the College of American Pathologists as a new client for its quality assessment products, which will be used in CAP’s global proficiency testing and external quality assessment programs for clinical laboratories. Multiple QAP product SKUs are already being supplied under confidential arrangements, with Microbix aiming to broaden its support across additional CAP programs and deepen the relationship through fiscal 2026 and beyond.

The deal underscores Microbix’s role as a specialist in safe, stable, patient-mimicking samples that validate diagnostic workflows end to end, leveraging its expertise in culturing and inactivating infectious disease pathogens. By aligning with CAP, one of the world’s leading laboratory quality organizations, Microbix enhances its industry positioning in lab quality assurance and potentially expands the reach and adoption of its QAPs among clinical labs that rely on CAP accreditation and proficiency testing services.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix to Release Q1 2026 Results and Host Investor Webinar on February 12

Microbix Biosystems Inc. will release its financial statements and management discussion and analysis for the first quarter of fiscal 2026, covering the period ended December 31, 2025, before markets open on February 12, 2026. On the same day at 10:00 a.m. ET, the company will host a webinar, led by its CEO, CFO and COO and organized by Adelaide Capital, to discuss its fourth-quarter 2025 results, with live access via Zoom and YouTube and a replay to be made available afterward, signaling continued efforts to engage investors and provide transparency around its financial performance and strategic direction.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Unveils FFPE-Simulated QC Platform to Standardize Molecular Pathology Testing

Microbix Biosystems is presenting new results from its novel Quality Assessment Products (QAPs™) platform for Molecular Pathology at the Labquality Days diagnostics conference in Helsinki, showcasing simulated formalin-fixed paraffin-embedded (FFPE) quality control materials designed to standardize and support nucleic-acid testing across laboratories. The data demonstrate that Microbix has created reproducible, homogeneous, and stable FFPE-simulated QC materials suitable for multiple molecular pathology methods and instruments, initially targeting assays for HPV, HSV, and Chlamydia trachomatis; this positions the company to fill a critical quality-control gap for molecular pathology labs, potentially strengthening its role in global diagnostics quality management and inter-laboratory standardization.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Tightens EBITDA Disclosure After OSC Review

Microbix Biosystems Inc., a Canadian life sciences manufacturer specializing in antigens, quality assessment products, and reference materials for the global diagnostics market, has operations spanning over 30 countries and also develops proprietary therapeutics and molecular diagnostic reagents under stringent international regulatory accreditations. The company has updated the investor presentation on its website to add required disclosures explaining its use of EBITDA, after Ontario Securities Commission staff flagged that earlier slides referenced this non-IFRS financial measure without sufficient detail on its composition, usefulness, and reconciliation to IFRS figures; the move reflects an effort to align its continuous disclosure materials more closely with Canadian securities rules and enhance transparency for investors.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Launches First Recombinant SARS-CoV-2 Antigen for QAPs and Test Makers

Microbix Biosystems has commercialized its first recombinant antigen product, the SARS-CoV-2 nucleocapsid protein, for use in its QAPs quality assessment line and for sale at commercial scale to test manufacturers, marking the first market-ready output from its recombinant antigen development program launched in 2025. By adding internally produced synthetic antigens to its long-established native antigen capabilities, the company aims to strengthen supply-chain security, cost control, and technical flexibility for quality assessment materials used in proficiency testing and clinical lab quality management, particularly for enduring SARS-CoV-2 testing needs, where related QAPs already represent a meaningful share of its C$5.6 million fiscal 2025 QAPs revenue.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Swings to Loss as China Demand Softens and Key Programs Are Cancelled

Microbix reported a challenging fiscal 2025, with full-year revenue falling 27% to $18.6 million and the company swinging from net income of $3.5 million in the prior year to a net loss of $2.2 million. The downturn was driven by the absence of prior-year licensing revenue from its Kinlytic asset, weaker antigen sales into China amid fewer respiratory infections, and the cancellation of test-development programs by a major QAPs client, all of which compressed gross margins from 61% to 53% and increased pressure from operating expenses. Fourth-quarter revenue declined 41% to $3.7 million, led by a 55% drop in antigen sales as Chinese demand softened and shipments to a large European customer were delayed, resulting in a quarterly net loss of $1.5 million and a sharp margin deterioration. Despite these setbacks, the company highlighted ongoing investments in manufacturing efficiency, new product development, and expanded client relationships, and it ended the year with a strong liquidity position, including $12.1 million in cash and a high current ratio, positioning it to pursue new products and customers to rebuild revenue above breakeven levels.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems to Announce Q4 2025 Financial Results

Microbix Biosystems Inc. has announced the upcoming release of its financial results for the fourth quarter of fiscal 2025, scheduled for December 18, 2025. The company will host a webinar to discuss these results, featuring its CEO, CFO, and COO. This announcement highlights Microbix’s commitment to transparency and engagement with its stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems Launches New Products to Enhance H3N2 Flu Testing

Microbix Biosystems Inc. has launched new QAPs™ quality assessment products and QUANTDx™ reference materials to support testing for the H3N2 strain of Influenza A, which is experiencing an antigenic drift, affecting immunity and test accuracy. The company’s new products are designed to ensure reliable detection of H3N2 variants, providing stability and accuracy for laboratories and test developers, thus supporting effective public health responses and improving healthcare outcomes globally.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix and Seegene Mexico Collaborate to Enhance HPV Test Accuracy

Microbix Biosystems Inc. and Seegene Mexico have partnered to enhance the accuracy of HPV tests across Mexico by utilizing Microbix’s quality assessment products with Seegene’s molecular multiplex assays. This collaboration aims to improve public health efforts for cervical cancer surveillance and ensure high international quality standards in clinical labs, with potential expansion into other infectious disease diagnostics.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.